The evolution of GLP-1 drugs from successful diabetes treatments to industry-shaping obesity products has brought with it critical quality control and regulatory compliance challenges.
This session will discuss how pharma manufacturers can ensure test methods’ analytical accuracy when identifying and controlling impurities, including:
- Tackling the inherent complexity of GLP-1 products
- Following best practice in quality assessments
- Preparing for the next wave of GLP-1 innovation, from small molecules and beyond
